Understand the Role of RNA in Myeloid Cancers
Myeloid malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)—often stem from complex genetic changes, particularly gene fusions and chromosomal translocations. These alterations are critical biomarkers in diagnosis and treatment decisions, making RNA sequencing for myeloid malignancies an essential tool for modern research and clinical applications.
RNA-based gene panel testing enables deeper molecular insights by:
Detecting fusion transcripts that DNA panels may miss
Supporting targeted therapies and personalized treatment strategies
Aiding in early diagnosis and subtype classification
Overcoming Detection Challenges with the Myeloid Profiler RNA Panel
Detecting fusion genes in myeloid cancers is complex due to:
Low expression levels
High genetic heterogeneity
Presence of rare or novel fusion events
The Myeloid Profiler RNA Panel, an advanced NGS myeloid gene panel addresses these challenges with:
Detection of 52+ key fusion genes and 600+ fusion variants
High sensitivity and specificity through optimized RNA capture technology
Compatibility with degraded or low-quality RNA samples
Product Overview: Next-Generation Fusion Gene Profiling
The Myeloid Profiler RNA Panel is a next-generation sequencing (NGS) assay engineered for comprehensive RNA fusion detection in myeloid malignancies.
Key Features:
Extensive Fusion Coverage: Identifies both known and novel gene fusions
Streamlined NGS Workflow: Designed for efficiency and reduced turnaround time
High Accuracy & Reproducibility: Enables confident clinical and research decision-making
Versatile Applications: Suitable for translational research, clinical diagnostics, and precision oncology studies
